Get the Stockscreener App
33.35
0.33%
-0.11
Pre-market:
33.47
0.12
+0.36%
Gsk Plc Adr stock is traded at $33.35, with a volume of 7.45M.
It is down -0.33% in the last 24 hours and down -13.49% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$33.46
Open:
$33.4
24h Volume:
7.45M
Relative Volume:
1.37
Market Cap:
$68.04B
Revenue:
$39.71B
Net Income/Loss:
$3.17B
P/E Ratio:
9.6883
EPS:
3.4423
Net Cash Flow:
$6.05B
1W Performance:
-5.01%
1M Performance:
-13.49%
6M Performance:
-25.21%
1Y Performance:
-5.01%
1-Day Range:
$33.19
$33.53
1-Week Range:
$32.83
$35.46
52-Week Range:
$32.83
$45.92
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Compare GSK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| GSK | 33.35 | 68.04B | 39.71B | 3.17B | 6.05B | 3.4423 |
| LLY | 753.41 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 105.27 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 153.11 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 167.76 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 97.44 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-24 | Downgrade | UBS | Buy → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| Mar-04-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients - Benzinga
5 Stocks to Buy While They’re Still Cheap After Earnings - Morningstar
Diabetes Care Nutrition Market Report 2024 with Forecasts to 2029 - GlobeNewswire Inc.
The 10 Best Companies to Invest in Now - Morningstar
Weekly Upgrades and Downgrades - InvestorPlace
The Best Defensive Stocks to Buy - Morningstar
GSK Plc ADR (NYSE: GSK) Has Outstanding Potential - Stocks Register
GSK (GSK) Q3 Earnings Surpass Estimates - Yahoo Finance
What Do Analysts Think About ICICI Bank Ltd. ADR’s (NYSE:IBN) Future? - Stocks Register
GSK Plc ADR (GSK): An Important Analyst Insights - Stocks Register
5 Stocks to Buy if You’re Concerned About US Market Valuations - Morningstar
21 Best Healthcare Companies to Invest In - Morningstar
Current share price is - GSK
D-Wave Quantum Inc (QBTS) rating initates by B. Riley Securities - Knox Daily
GSK's Studies On Depemokimab For Nasal Polyps Meet Primary Goals - Barchart
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
GSK Plc ADR [GSK] is 5.59% higher this YTD. Is it still time to buy? - The DBT News
What You Didn’t Know About General Motors Company (NYSE: GM) This Week - Stocks Register
GSK’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Before You Invest, Make Sure You Check This ADT Inc (NYSE: ADT) Analysis - Stocks Register
What Are You Thinking About Investing In Medical Properties Trust Inc (NYSE: MPW) Stock? - Stocks Register
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday - sharewise
Introducing Our Rant Against GSK Plc ADR - US Post News
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy - Zacks Investment Research
Balance Sheet Insights: GSK Plc ADR (GSK)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Pilgrim’s Pride Corp. (PPC) receives an Equal-weight rating from Stephens - Knox Daily
Berenberg upgrades Carnival plc ADR (CUK) stock to a Hold - Knox Daily
JP Morgan analysts downgrades an Underweight rating for Organon & Co. (OGN) - Knox Daily
GSK Plc ADR (GSK) gets rating Downgrade from UBS - Knox Daily
GSK Plc ADR (GSK) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
Precidian to List First ADRhedged Securities in the U.S. on Cboe, Providing Exposure to Individual International Companies with an Embedded Currency Hedge - PR Newswire
Tenet Healthcare Corp. [THC] stock for 1,879,734 USD was sold by Ramsey R. Scott - Knox Daily
Ratio Analysis: Unpacking GSK Plc ADR (GSK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GSK Plc ADR [GSK] Insider Activity: An Update for Investors - Knox Daily
GSK Plc ADR (GSK) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Cantor Fitzgerald’s latest rating for AMGN stock - Knox Daily
Nutanix Inc [NTNX] Chief Financial Officer makes an insider sale of 24,316 shares worth 1,430,939. - Knox Daily
GSK’s Stock Market Adventure: 9.44% YTD Growth Amidst Volatility - The InvestChronicle
GSK Shares Experience Decline in Value - Knox Daily
The Best Healthcare Stocks to Buy - Morningstar
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
2.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):